Internal Medicine / Oncology

The Washington University physicians in the Department of Internal Medicine encompass 14 specialty clinical divisions.

Over 270 physicians in the department of medicine treat patients with a wide range of diseases, disorders and conditions.

Text Size: S M L

Home > Physicians Directory > Internal Medicine / Oncology

Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP

Specialty Areas
Oncology
Medical Oncology
Breast Oncology
Breast Health

Learn more about Dr. Ellis

Patient Power Minute


Areas of Clinical Interest
Cancer, breast cancer

Areas of Research Interest
Insulin-like growth factor signaling and breast cancer, endocrine therapy for breast cancer, signal transduction therapy for breast cancer, preoperative systemic therapy for breast cancer, array based analysis of breast cancer gene expression, breast cancer clinical trial correlative science

Major or Recent Publications/Awards

Honors and Awards

Listed in Best Doctors in America, 2005-2009 (Best Doctors, Inc)
Listed in America's Top Doctors, Castle Connolly Medical LTD, 2008

Fellow, Royal College of Physicians

Editorial Responsibilities

Contributing Editor:
Breast Cancer

Editorial Board:
Journal of Clincal Oncology

Books and Book Chapters

Ellis MJ. Breast Cancer Gene Expression Analysis: The Case for Dynamic Profiling. In: New Trends in Cancer for the 21st Century. Eds Llombart-Bosch A and Felipo V. Kluwer Academic/Plenium Publishers, 2003

Coope A, Ellis MJ. The Genetics of Inherited Cancers. Oxford Textbook of Medicine, 4th Edition, p 229-237, Oxford University Press, 2003

Coope A, Ellis MJ. The Nature and Development of Cancer. In: Oxford Textbook of Medicine, 4th Edition, p 219-228, Oxford University Press, 2003

Chiu S, Ellis MJ. Endocrine Therapy for Advanced Breast Cancer. In: International Handbook of Breast Cancer, p 121-138, Ed. Johnson S. Euromed Publications, 2002

Ellis MJ. Neoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist's Perspective. In: WR Miller and JN Ingle (eds), Endocrine Therapy in Breast Cancer, pp 181-195. New York: Marcel Dekker, 2002

Ellis MJ, Swain S. Steroid Hormone Therapies for Cancer, In: Cancer Chemotherapy and Biotherapy 3rd Edition. Eds, Chabner BA and Longo DL, Lippincott, Williams and Wilkins, 2001

Ellis MJ, Hayes, DF, Lippman ML. Treatment of Metastatic Breast Cancer In Diseases of the Breast 2nd Edition. Eds: Harris JR, Lippman ME, Morrow M, Osborne CK. Lippencott Williams and Wilkins, 1999

Publications

Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clinical Cancer Research, In press

Wong ZW, Ellis MJ. First line endocrine therapy for breast cancer: aromatase inhibitor or antiestrogen? British J Cancer, In press

Wong, ZW, Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: An overlooked option in the United States? Oncology, In press

Ellis MJ, Coop A, Singh B, Tao Y, Llombert-Cussac A, Janaeke F, Mauriac L, Evans DB. Quebe-Fehling E, Chaudri-Ross HA, Miller WR. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression: Cancer Research, In press

Ellis MJ, Rosen E, Dressman H, Marks J. Neoadjuvant comparison of aromatase inhibitors and tamoxifen: Pretreatment determinanats of response and on-treatment effect. J Steroid Biochemistry and Mol Biol, In press

Ellis MJ. Breast cancer gene expression analysis - the case for dynamic profiling. Adv Exp Med Biol, 532:223-234, 2003

Dowsett M, Ellis MJ. Role of biologic markers in patient selection and application to disease prevention. American Journal of Clinical Oncology, 2003; 26(4):S34-9

Stearns V, Singh B, Tsangaris T, Crawford J, Noveilli A, Ellis MJ et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clinical Cancer Research, 2003; 9:124-133

Osborne CK, Pippen J, Jones SE, Parker LM, Ellis MJ, Come S, Gertler SZ, May JT, Burton G, Dimerly I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fluvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American Trial. JCO, 2002; 3386-95

Ellis MJ, Davies N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell C, Singh B, Miller W, Stearns V, Pennannan M, Tsangaris T, Gallagher A, Aiyi A, Zwart A, Hayey DF, Lippman ME, Wang Y, Clarke R. Development and validation of a madel for using breast core needle biopsies for gene expression microarray analysis. Clinical Cancer Research, 2002 8:1155-1166

Shaw HS, Ellis MJ. Letrozole in the treatment of breast cancer. Expert Opinion on Pharmacotherapy 2002; 3:607-615

Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: Medical perspectives. Clinical Cancer Research, 7:4388s-4391s, 2001

Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans, DB, Dugan M, Brady C, Quebe-Fehling E, Borgs, M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or ErbB2 positive, estrogen receptor positive primary breast cancer: Evidence from a phase 3 randomized trial. Journal of Clinical Oncology, 19:3808-3816, 2001

Dressman, M, Lavedan C, Barnes L, Buchholtz S, Kwon I, Walz TM, Ellis MJ, Polymeropoulos MH. Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. The Pharmacogenomics Journal, 1:135-141, 2001

Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea. Cancer Control Journal, 7:557-562, 2000

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Ellis